Bioage plans mid-year IND submission for BGE-102 for obesity

May 30, 2025

Bioage Labs Inc. has completed IND-enabling studies for BGE-102, a structurally novel, orally available small-molecule NLRP3 inhibitor.

AI generated illustration of a brain on fire

Neurology/psychiatric

Bioage nominates NLRP3 inhibitor as development candidate

Jan. 29, 2025

Bioage Labs Inc. has nominated BGE-102 as a development candidate. The orally available, small-molecule NLRP3 inhibitor has high potency and high brain penetration.

Today's news in brief

BioWorld

BioWorld briefs for Dec. 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 18, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Maintenance, man: Lilly’s phase III weight trial hits goals

BioWorld

Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...